In the article by Nick et al entitled “Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis,” which appeared in the December 15, 2004, issue of Blood (Volume 104:3878-3885), the lipopolysaccharide (LPS) administered to volunteers was incorrectly described: the wrong E coli strain was described. The LPS used in the study was actually derived from E coli strain O:113 (provided by the National Institutes of Health, Bethesda, MD).
Copyright © 2005 by The American Society of Hematology
2005